Steven Zelenkofske D.O. currently is Chief Medical Officer at SwanBio Therapeutics, a gene therapy company specializing in neurologic disease. Dr. Zelenkofske brings more than 20 years of industry development experience, most recently as Chief Medical Officer of Achillion Pharmaceuticals a clinical stage company specializing in complement inhibitors and at UniQure, a clinical stage gene therapy company. Previously he served as Chief Medical Officer of Regado Biosciences. He has also held leadership positions at Astra-Zeneca, Sanofi-Aventis, Boston Scientific and Novartis. Dr. Zelenkofske has been responsible for multiple NDA filings and has worked across multiple therapeutic areas including cardiovascular, metabolic diseases, diabetes, nephrology, hematology, immunology and neurology.

Dr. Zelenkofske completed his residency training at Philadelphia College of Osteopathic Medicine, followed by fellowships in cardiology and electrophysiology at The Graduate Hospital, Philadelphia, and St. Luke’s Hospital, New York, respectively. He is a graduate of Emory University, where he also earned a Master of Science degree in immunopharmacology. He earned his Doctor of Osteopathy from Philadelphia College of Osteopathic Medicine. He is a fellow of the American College of Cardiology, the American College of Chest Physicians, and the American College of Osteopathic Internists.

Dr. Arepally is Professor of Medicine and Vice Chief of Research in the Division of Hematology at Duke University Medical Center. Her career has focused on immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders. Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT, research that led to the discovery of the role of complement activation in the immune pathogenesis of HIT. Dr. Arepally received her MD from Vanderbilt University, completed residency in Internal Medicine at Emory University where she was Chief Medical Resident and finished subspecialty training in Hematology/Oncology at the University of Pennsylvania.

Dr. Cuker is Associate Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania. He also serves as Director of the Penn Comprehensive Hemophilia & Thrombosis Program, Assistant Director of the Penn Specialized Coagulation Laboratory, and Associate Director of the Penn-CHOP Blood Center for Patient Care and Discovery. He conducts NIH-funded patient-oriented research on heparin-induced thrombocytopenia, venous thromboembolism, and anticoagulation. Dr. Cuker received his MD from Yale University, completed an internship and residency in internal medicine at Brigham and Women’s Hospital and Harvard Medical School, and completed a fellowship in hematology/oncology at the Hospital of the University of Pennsylvania. He served as Chair of the 2018 American Society of Hematology Clinical Practice Guideline Panel on heparin-induced thrombocytopenia.

Dr. Michael Holinstat is a world-renowned expert in platelet physiology and pharmacology, with more than 70 peer-reviewed publications in the field. Dr. Holinstat’s laboratory at the University of Michigan focuses on understanding the complex signaling mechanisms which regulate hemostasis and thrombosis, and identifying novel approaches to anti-thrombotic therapy. Importantly, he is co-inventor of Veralox’s clinical product candidate. Dr. Holinstat leadership roles at the University of Michigan include 1) director for the MS degree in clinical research, 2) director for the Platelet Physiology and Pharmacology Core, and 3) therapeutic champion for the Fast Forward Medical Innovations commercialization program. Dr. Holinstat is a recipient of the Kenneth M. Brinkhous Young Investigator Prize in Thrombosis from the American Heart Association for his work on 12-lipoxygenase in cardiovascular medicine and is an elected fellow of the American Heart Association. Dr. Holinstat received his PhD in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University. He currently serves on numerous external boards including: 1) grant review boards for the US National Institutes of Health (NIH), French National Research Agency (ANR), UK Medical Research Council (MRC), 2) journal reviewer for Nature, JCI, Blood, and ATVB, and 3) serves on the editorial board for Frontiers in Pharmacology and Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).

Dr. Steven McKenzie received his MD and PhD from Perelman School of Medicine at the University of Pennsylvania. He did clinical training and postdoctoral research training at the Children’s Hospital of Philadelphia and the University of Pennsylvania. Dr. McKenzie is Thomas D.M. Cardeza Professor of Medicine and Director of Hematology and the Cardeza Foundation for Hematologic Research at Sidney Kimmel Medical College of Thomas Jefferson University. He is a world-renowned physician-scientist and expert in platelet biology, with a focus on immune-mediated thrombocytopenia and thrombosis syndromes. He also is co-inventor of VLX-1005 and developer of the gold standard clinically relevant heparin-induced thrombocytopenia and thrombosis mouse model utilized by the research community.

Dr. Mirmira is a Professor and Director of the Translational Research Center at the University of Chicago. He is an expert in the biology of the pancreatic islet as it relates to the pathogeneses of type 1 and type 2 diabetes. Dr. Mirmira’s team showed that 12-lipoxygenase contributes to islet oxidative stress in the setting of diabetes, and that the deletion or inhibition of 12-lipoxygenase in islets of mice enhances insulin secretion and prevents hyperglycemia. He has published more than 130 scientific papers in prestigious journals and is an international thought leader in the field of diabetes. Dr. Mirmira received an MD/PhD from The University of Chicago and completed his residency in Internal Medicine with subspecialty training in Diabetes and Endocrinology at the University of California at San Francisco.

Dr. Ted Warkentin is Professor in the Department of Medicine and the Department of Pathology and Molecular Medicine at the Michael G. DeGroote School of Medicine, McMaster University, in Hamilton, Ontario, Canada. He is also a clinical and laboratory hematologist, in the Service of Benign Hematology, at Hamilton Health Sciences. Dr. Warkentin received his M.D. from the University of Manitoba and completed a hematology research fellowship at McMaster and postgraduate work in medicine and hematology at the University of Toronto and McMaster University. Dr. Warkentin is a Fellow of the Royal College of Physicians and Surgeons of Canada, and of Edinburgh, as well as of the American College of Physicians. He was awarded the XV^th Jean Julliard Prize at the XXIV^th Congress of the International Society of Blood Transfusion (Makuhari, Japan; in 1996), and was a Co-Winner of the 2015 Prix Galien Canada, for work on heparin-induced thrombocytopenia (HIT). He was the 2018 recipient of the Stephen Garnett Distinction Award, given to a Hamilton Health Sciences physician for exemplary medical service, education, and research. Dr. Warkentin is the former Chair (four-year term ended 2007) of the Platelet Immunology Committee of the Scientific and Standardization Committee (SSC; International Society on Thrombosis and Haemostasis [ISTH]) and was the Chair of the 2004 and 2008 consensus conference guidelines on HIT, written under the aegis of the American College of Chest Physicians (ACCP). Dr. Warkentin devised the “4Ts” scoring system for estimating pretest probability of HIT. He also was a Member of the American Society of Hematology (ASH) Guideline Panel (2015 – Nov 2018), culminating in the ASH HIT diagnosis and treatment guidelines (Blood Advances 2018).

Mr. Martin is Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. He previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX) where he now serves as a Director. Mr.Martin was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). Mr.Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Mr. Martin is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. Mr. Martin holds a BA from Cornell University and an MBA from Harvard.

Katie Ellias joined the T1D Fund in July 2018 as a Managing Director from Endeavour Vision, a Geneva-based growth stage venture fund, where she focused on medical devices and digital health as Senior Investment Director. She was previously Principal at Sofinnova Partners, Paris, a leading early stage life sciences fund, investing in medical technologies. She served as Board Observer for ReCor Medical (sold to Otsuka Holdings), CorWave, Shockwave Medical (NASDAQ: SWAV), RefleXion Medical, Pixium Vision (PIX.PA), and MD Start, a medical device accelerator. Katie holds a MBA in Healthcare Management from the Wharton School at the University of Pennsylvania and a BA cum laude in International Relations and Political Science from Yale University.

Meg is Director of Investments at Sanofi Ventures, the corporate venture capital arm of Sanofi. Prior to joining Sanofi Ventures, Meg was Director of Business Development, External Innovation at Vertex Pharmaceuticals. Previous to Vertex, Meg was a Senior Associate at RA Capital, where she supported public and private investments across a variety of areas including genetic medicines, rare disease, and neuroscience. Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and B.S. with Distinction and Honors in Neuroscience from The Pennsylvania State University.

Ben is a Principal at Hatteras Venture Partners, where he supports the firm’s overall operations, existing portfolio strategy, deal flow activities, and due diligence. Prior to joining Hatteras in 2016, Ben was a postdoctoral fellow in the Epigenetics and Stem Cell Biology Laboratory at the National Institute of Environmental Health Sciences. He has performed research in the fields of genomics, metabolism, RNA biology, and transcription regulation. Ben serves as a director on the board of IMMvention Therapeutix. He also serves as a board observer at Altis Biosystems, Dropworks, Myeloid Therapeutics, Qpex Biopharma, and Trefoil Therapeutics, and he was formerly a board observer at Graybug Vision (Nasdaq: GRAY). Ben received his B.E. in biomedical engineering from Vanderbilt University and a Ph.D. in molecular cell biology from Washington University in St. Louis.

Jamie joined Genesys Capital in 2002 and became Partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in twelve early stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include EBT Medical, Fairhaven Pharmaceuticals and Inversago Pharma. Past board affiliations include Allostera Pharma, gIcare Pharma, Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Jamie also volunteers as a board member for BioteCanada, and an advisor to both the Ontario Genomics Institute (OGI) and the Centre for Commercialization of Regenerative Medicine (CCRM) and as an associate with Creative Destruction Lab (CDL).

Prior to joining Genesys, Jamie worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Jamie completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.

Peter is an experienced life-science industry executive with over forty years’ experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager and CEO and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs in the vaccine/biologics and specialty pharmaceutical sectors. At Glaxo Wellcome in the mid-1990s he led the global introduction of combination HIV therapy while keying industry leadership on global treatment access.

Currently Peter serves as a senior venture partner with Pappas Capital, where he leads the firm’s initiatives in translational medicine and served for many years as the firm’s Program Manager for Wake Forest Baptist Medical Center’s seminal Technology Development Program. He also serves as an Executive in Residence at Cold Spring Harbor Laboratories and the Center for Biotechnology at Stony Brook University, and as a Mentor in Residence in Rutgers’ Health Advance program, as well as on the board of directors of several start-up life science companies. He is a member of the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, the Long Island Bioscience Hub External Review Board and the Long Island BioMentor Initiative, the Scientific Advisory Board of New York’s Empire Discovery Institute, a member of Washington University’s Therapeutics Domain Expert Program, a past member of the BIO board and chairman of the North Carolina Biosciences Organization, and a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009.

Peter has lived and worked in the US, Greece and the Middle East, Puerto Rico, New Zealand, and London, and currently lives with his family in New York. He has a BA and an MBA from Indiana University.

Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management and is the chief executive officer of Veralox. Previously he served as the chief executive officer of PhaseBio Pharmaceuticals (NASDAQ) where he led the company from early stages through Phase 3 development, including the company’s IPO in 2018. Prior to PhaseBio, Jonathan served as vice president, business development for Amylin Pharmaceuticals until its sale to Bristol-Myers Squibb in 2012; co-founder and vice president, commercial and business development of Corus Pharma, Inc. until its acquisition by Gilead Sciences in 2006; and head of business development for PathoGenesis Corporation, until it’s acquisition by Chiron Corporation in 2000. Jonathan has also held positions in marketing, marketing research and sales at Bristol-Myers Squibb, Wyeth/Lederle International and Syntex Laboratories. Jonathan holds a BS in Mechanical Engineering from UC Berkeley and an MBA from Carnegie Mellon University Tepper School of Business.